Clinical trial
Pearl Index Study With Low Dose Combined Oral Contraceptive
NCT00220324 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00220324 |
|---|---|
| Title | Pearl Index Study With Low Dose Combined Oral Contraceptive |
| Official title | Prospective, Multicenter, Open-label, Uncontrolled Study to Investigate the Contraceptive Efficacy, Bleeding Patterns, and Safety of an Oral Contraceptive Containing 0.03 mg Ethinylestradiol and 0.125 mg Levonorgestrel (SH D00342A) Applied for 13 Cycles to Healthy Female Volunteers |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Contraception |
| Intervention type | Drug |
| Interventions | Minisiston (SH D00342A) |
| Enrollment | 840 |
| Start date | Feb 1, 2004 |
| Completion | Nov 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 3, 2015 |
| Countries | Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: